Civic AI
Procurement intelligence
Federal contract award
TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1.
ABVIRO LLC · Department of Health and Human Services
- Value
- $11,335,102
- Start
- Sep 25, 2023
- End
- Dec 31, 2026
- Action date
- Mar 24, 2026
- PIID
- 75N93023C00055
- Status
- active
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- BETHESDA, MD
- Award type
- DEFINITIVE CONTRACT
Description
TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1.
Need modifications, related awards, and vendor peers? Open the full award workspace.